PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
down 21%, driven by a negative impact from the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. 7) BNT162b2 has not been approved or licensed by the U.S. Hospital products, which grew 10% operationally to $2.3 Chantix in the U.S.,
40 
Let's personalize your content